Publikationen

14.11.2006


Achtung: Diese Liste wird zur Zeit aktualisiert

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol. 2007; 136: 191-202

Dreyling M, Trumper L, von Schilling C, et al. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy. Ann Hematol. 2007 Feb;86(2):81-7

Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C.: Investigational strategies in autologous stem cell transplantation for follicular lymphoma.Curr Oncol Rep. 2006 Sep;8(5):368-75.

Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dorken B, Freund M, Huber C, Ganser A, Trumper L, Forstpointner R, Unterhalt M, Hiddemann W. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Ann Oncol. 2007; 18: 136-142

Forstpointner R, Unterhalt M, Dreyling M, Böck H-P, Repp R, Wandt H, Pott C, Seymour J, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W: Maintenance Therapy with Rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of Rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas – Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 108(13):4003-4008

Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trümper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W for the German Low Grade Lymphoma Study Group (GLSG)* CHOP improves Response Rates but not Survival and has a lower Hematologic Toxicity as compared to MCP in Follicular and Mantle Cell Lymphomas – Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). Cancer 2006

Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006 May 11;

Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Bruggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling M, Hiddemann W, Siebert R, Dreger P, Kneba M. Quantitative assessment of molecular remission following high-dose therapy with autologous stem cell transplantation predicts long term remission in mantle cell lymphoma. Blood 107: 2271-78, 2006

G. Lenz and M. Dreyling: Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL ? Nature Clin Practice Oncol 2: 2-3, 2005

Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, Berger F, Kluin P, Ott G, Pileri S, Pedrinis E, Feller AC, Merz H, Janssen D, Hansmann ML, Krieken H, Moller P, Stein H, Unterhalt M, Hiddemann W, Parwaresch R: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 131(1):29-38, 2005

W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, T. Fischer, M. Kropff, H.-E. Reis, M. Freund, B. Wörmann, R. Fuchs, M. Planker, J. Schimke, H. Eimermacher, L. Trümper, A. Aldaoud, R. Parwaresch, and M. Unterhalt: Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone – results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 106: 3725-3732, 2005

G. Lenz, M. Dreyling, E. Hoster, B. Wörmann, U. Dührsen, B. Metzner, H. Eimermacher, A. Neubauer, H. Wandt, H. Steinhauer, S. Martin, El. Heidemann, A. Aldaoud, R. Parwaresch, J. Hasford, M. Unterhalt and W. Hiddemann: Immuno-Chemotherapy with Rituximab and CHOP significantly improves Response and Time to Treatment Failure but not long-term Outcome in Patients with previously untreated Mantle Cell Lymphoma – Results of a prospective randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984-1992, 2005

G. Lenz, M. Dreyling, E. Schiegnitz, M. Unterhalt, and W. Hiddemann: Myeloablative Consolidation and autologous stem cell transplantation in first remission significantly prolongs duration of remission in follicular lymphoma. Am L Oncol Review 4: 87-90, 2005

G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, W. Hiddemann: Moderate increase of secondary hematologic malignancies following myeloablative radiochemotherapy and autologous stem cell transplantation in patients with indolent lymphoma – results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG: J Clin Oncol 22(24):4926-33, 2004

M. Dreyling, G. Lenz, E. Hoster, A. Van Hoof, C. Gisselbrecht, R. Schmits, B. Metzner, L. Truemper, M. Reiser, H. Steinhauer, J. Boiron, M.Boogaerts, A. Aldaoud, , V. Silingardi, H. Kluin-Nelemans, J. Hasford, R. Parwaresch, M. Unterhalt and W. Hiddemann: Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous Stem Cell Transplantation in First Remission significantly prolongs Progression-Free Survival in Mantle Cell Lymphoma - Results of a Prospective Randomized Trial of the European MCL Network. Blood 105: 2677-2684, 2005

G. Lenz, M. Dreyling, E. Schiegnitz, R. Forstpointner, H. Wandt, M. Freund, G. Hess, L. Truemper, V. Diehl, M. Kropff, M. Kneba, N. Schmitz, B. Metzner, M. Pfirrmann, M. Unterhalt, and W. Hiddemann: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma - results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 104: 2667-2674, 2004

R Forstpointner, M Dreyling, R Repp, S Hermann., A Hänel, B Metzner, C Pott, F Hartmann, F Rothmann, R Rohrberg, H-P Böck, H Wandt, M Unterhalt, W Hiddemann: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group Blood 104: 3064-1071, 2004

W Hiddemann, M Dreyling: Mantle Cell Lymphoma: Therapeutic strategies are different from CLL.Curr Treat Options Oncol 4(3): 219-26, 2003

W Hiddemann, M Dreyling, M Unterhalt: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 81 (Suppl 2): 16-20, 2003

M.H. Dreyling: Indolent Lymphoma: new and old therapeutic options in the scope of the WHO classification. Hematologie 6 (Suppl.Nr 4): 3-5, 2000

W. Hiddemann, M. Dreyling, M. Tiemann, C. Schrader , M. Unterhalt for the European Mantle Cell Study Group: Mantle cell lymphomas. Haematologica 84: 93-95, 1999